Localized prostate cancer: a molecular signature to identify non-aggressive tumours

Although prostate cancer is the most frequent cancer in men, only 15% of patients will eventually develop a metastatic disease. However, immediate radical surgery (prostatectomy) remains a standard of care for localized prostate tumours, and may lead to many complications impacting patient’s quality of life. Actual clinical and molecular tools do not accurately identify patients with non-evolutive/indolent tumours. A CIT study carried out in collaboration with Professor O.Cussenot, Head of the Urology Department at Paris Est University Hospital, led to the identification of a molecular subtype of tumours accounting for 20% of patients with localized prostate cancer and highly predictive of a non-evolutive disease. This work also provides a set of robust biomarkers as a clinical diagnostic tool to accurately identify these tumours. Using this molecular subtyping, active surveillance could be systematically proposed as a standard of care to 1 over 5 patients with localized prostate cancer, therefore saving them from radical surgery.

Kamoun, A., Cancel-Tassin, G., Fromont, G., Elarouci, N., Armenoult, L., Ayadi, M., Irani, J., Leroy, X., Villers, A., Fournier, G., et al. (2018). Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of a non-aggressive disease. Ann. Oncol.